9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          TransCelerate reports on the results of 2019, 2020, and 2021 member company (MC) surveys on the use of intelligent automation in pharmacovigilance processes. MCs increased the number and extent of implementation of intelligent automation solutions throughout Individual Case Safety Report (ICSR) processing, especially with rule-based automations such as robotic process automation, lookups, and workflows, moving from planning to piloting to implementation over the 3 survey years. Companies remain highly interested in other technologies such as machine learning (ML) and artificial intelligence, which can deliver a human-like interpretation of data and decision making rather than just automating tasks. Intelligent automation solutions are usually used in combination with more than one technology being used simultaneously for the same ICSR process step. Challenges to implementing intelligent automation solutions include finding/having appropriate training data for ML models and the need for harmonized regulatory guidance.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: not found
          • Article: not found

          A Study on the Application and Use of Artificial Intelligence to Support Drug Development

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Automation Opportunities in Pharmacovigilance: An Industry Survey

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities

              There are significant challenges and opportunities in deploying and utilizing advanced information technology (IT) within pharmacovigilance (PV) systems and across the pharmaceutical industry. Various aspects of PV will benefit from automation (e.g., by improving standardization or increasing data quality). Several themes are developed, highlighting the challenges faced, exploring solutions, and assessing the potential for further research. Automation of the workflow for processing of individual case safety reports (ICSRs) is adopted as a use case. This involves a logical progression through a series of steps that when linked together comprise the complete work process required for the effective management of ICSRs. We recognize that the rapid development of new technologies will invariably outpace the regulations applicable to PV systems. Nevertheless, we believe that such systems may be improved by intelligent automation. It is incumbent on the owners of these systems to explore opportunities presented by new technologies with regulators in order to evaluate the applicability, design, deployment, performance, validation and maintenance of advanced technologies to ensure that the PV system continues to be fit for purpose. Proposed approaches to the validation of automated PV systems are presented. A series of definitions and a critical appraisal of important considerations are provided in the form of use cases. We summarize progress made and opportunities for the development of automation of future systems. The overall goal of automation is to provide high quality safety data in the correct format, in context, more quickly, and with less manual effort. This will improve the evidence available for scientific assessment and helps to inform and expedite decisions about the minimization of risks associated with medicines.
                Bookmark

                Author and article information

                Contributors
                neal.grabowski@abbvie.com
                Journal
                Drug Saf
                Drug Saf
                Drug Safety
                Springer International Publishing (Cham )
                0114-5916
                1179-1942
                17 May 2022
                17 May 2022
                2022
                : 45
                : 5
                : 439-448
                Affiliations
                [1 ]GRID grid.418019.5, ISNI 0000 0004 0393 4335, GlaxoSmithKline, Global Safety, ; Upper Providence, PA USA
                [2 ]GRID grid.431072.3, ISNI 0000 0004 0572 4227, AbbVie, Pharmacovigilance and Patient Safety Business Process Office, ; North Chicago, IL USA
                [3 ]GRID grid.420044.6, ISNI 0000 0004 0374 4101, Bayer AG, Medical Affairs and Pharmacovigilance, Pharmaceuticals, ; Berlin, Germany
                [4 ]Merck Healthcare, Case and Vendor Management-Global Patient Safety, Darmstadt, Germany
                [5 ]GRID grid.418158.1, ISNI 0000 0004 0534 4718, Genentech, A Member of the Roche Group, ; South San Francisco, CA USA
                [6 ]GRID grid.496862.7, ISNI 0000 0004 0544 6263, Novartis, Chief Medical Office and Patient Safety, , Novartis Global Drug Development, ; Dublin, Ireland
                [7 ]GRID grid.8217.c, ISNI 0000 0004 1936 9705, Trinity College, ; Dublin, Ireland
                [8 ]MSD, R&D IT, Prague, Czech Republic
                [9 ]GRID grid.417886.4, ISNI 0000 0001 0657 5612, Amgen, Pharmacovigilance Operations, ; Los Angeles, CA USA
                [10 ]GRID grid.421932.f, ISNI 0000 0004 0605 7243, UCB, IT Patient Safety, ; Brussels, Belgium
                Author information
                http://orcid.org/0000-0002-7025-2508
                Article
                1164
                10.1007/s40264-022-01164-5
                9114066
                35579809
                c7f30fed-5b7f-4124-90a9-57a2fbb71d62
                © TransCelerate BioPharma Inc. 2022

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 17 February 2022
                Funding
                Funded by: TransCelerate BioPharma, Inc.
                Categories
                Leading Article
                Custom metadata
                © Springer Nature Switzerland AG 2022

                Comments

                Comment on this article